Clinical momentum Immusoft is actively presenting clinical data on engineered B cells at major conferences (ASGCT 2025 and 2026) and has upcoming posters in 2026, signaling a continuous pipeline advancement and opportunities to engage in discussions around ongoing trials, collaboration, and potential co-development arrangements.

Financial support Recent $15 million funding from the California Institute for Regenerative Medicine strengthens balance sheet and provides a narrative for near-term expansion in early-stage trials, enabling BD conversations around funded programs, in-state partnerships, and potential grant-aligned programs.

Therapeutic focus Core platform Immune System Programming targets sustained delivery of therapeutic proteins via patient-derived B cells, offering a unique value proposition for rare diseases with high unmet need and potential to partner on specific indications where durable, living protein therapies could outperform conventional approaches.

Strategic partnerships Past collaboration with Takeda underscores openness to external partnerships in enabling B cell–based therapies and blood-brain barrier targets, suggesting a receptive posture for BD outreach focused on alliance opportunities, co-development, and capability licensing.

Market positioning Revenue trajectory reported in the low single digits with a mid-sized funding runway places Immusoft as a niche, research-forward biotech with potential for early partnering to accelerate trials, expand manufacturing footprint, or license ISP technology for rapid entry into selective rare-disease programs.